Prolactin in high-metabolic risk pregnancies: Associations with maternal obesity and metabolic health
Abstract
Introduction: Low prolactin levels during pregnancy have been linked to adverse maternal metabolic health. We examined pregnancy prolactin levels in relation to maternal metabolic characteristics within an ethnically diverse cohort at high metabolic risk.
Material and methods: In this observational cohort study, pregnant women (n = 130) with metabolic risk factors were characterized in early pregnancy, with sampling of serum prolactin and metabolic parameters. Fifty-four women with gestational diabetes consented to serial profiling across pregnancy. Univariable and multivariable simple and mixed-effects regression models examined relationships between prolactin and maternal variables.
Results: Women with obesity (BMI ≥30 kg/m2) had lower early pregnancy prolactin levels than women without obesity (35.1 vs 44.3 μg/L, p = 0.03). Lower prolactin in early pregnancy was associated with higher parity and higher early pregnancy BMI, fasting insulin, insulin resistance, and diastolic blood pressure, but only relationships with parity and BMI persisted after adjustment for covariates. In the serially sampled cohort, lower prolactin levels across pregnancy were independently associated with higher pre-pregnancy maternal BMI (adjusted β = -3.25, p = 0.04). Lower absolute prolactin increment from early to late pregnancy was independently associated with higher pre-pregnancy and early pregnancy maternal BMI (p = 0.046 and p = 0.04, respectively).
Conclusions: Maternal metabolic status,…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 130 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.